Immunotherapy plus chemo shows promise for esophageal cancer before surgery

NCT ID NCT07437898

Recruiting now Disease control Sponsor: The Affiliated Hospital of Putian University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether giving the immunotherapy drug adebrelimab along with standard chemotherapy before surgery can help people with locally advanced esophageal cancer. About 42 participants will receive the treatment every 3 weeks, then have surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adebrelimab (an immunotherapy drug) plus chemotherapy (nab-paclitaxel and cisplatin)
What this could lead to: If successful, this combination could become a standard pre-surgery treatment to shrink tumors and improve survival for esophageal cancer patients.
What could go wrong: This is a small, early-phase trial with only 42 participants, so results may not apply broadly. Side effects from immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

The Affiliated Hospital of Putian University
RECRUITING

Putian, Fujian, 351100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.